A Study Evaluating the Ability of Experimental Medications to Improve Health Outcomes for People with COVID-19

Official Title: National Institute of Allergy and Infectious Diseases / “Adaptive Platform Treatment Trial for Outpatients with COVID-19 (Adapt Out COVID)”


The purpose of this study is to evaluate the ability of various experimental drugs to improve health outcomes for people with COVID-19. We also want to see if these study drugs are safe, and if these study drugs can
stop the disease process and prevent hospitalization. This study is designed to quickly identify safe and effective drugs that may treat COVID-19.

Participants in the study will be treated with either a study drug or with placebo ( looks like a “real” drug, but it does not have any active drug in it).

Eligibility criteria:

- Adult 18 or older
- Active SARS-CoV-2 infection less than 7 days prior to Entry
- At least one typical COVID-19 symptom for less than 10 days prior to Entry, plus one the following symptoms present within 48 hours of entry:
o Fever or feeling feverish
o cough
o shortness of breath at rest or with activity
o sore throat
o body or muscle pain
o fatigue
o headache
o chills

Contact Information

Kathy Watson